Neurology Week 2022 Recap: Experts Convene to Provide Practical Clinical Education With the Goal of Improving Patient Outcomes

The second annual Neurology Week virtual education experience recently convened from September 7th through 10th for 4 days of practical education from leading minds in the neurology field to provide attendees with “practice-changing applications and insight.”

The conference opened with state-of-the-field sessions, including a thorough overview of progressive multiple sclerosis (MS) from Neurology Learning Network Section Editor Patricia Coyle, MD, FAAN, FANA, vice chair (clinical affairs), professor of neurology, director of MS Comprehensive Care Center, Stony Brook University Hospital. Dr Coyle led attendees through the distinctions between progressive MS versus relapsing MS, as well as current and future potential therapies for both manifestations of the disease.

Attendees watched experts discuss the latest clinical research including emerging trial results and cutting-edge therapies; heard first-hand accounts of and clinical guidance for difficult neurological cases; and left equipped with the latest methods and data in the field, ready to implement them into their clinical practice to improve patient care. Below are some highlights from each day of the virtual conference.

Day 1:

• Victor Sung, MD, associate professor, director of Huntington’s Disease Clinic, University of Alabama at Birmingham, and Craig Chepke, MD, FAPA, adjunct associate professor of psychiatry, Atrium Health, adjunct assistant professor of psychiatry, UNC School of Medicine, and medical director, Excel Psychiatric Associates, Huntersville, North Carolina, addressed “persistent myths and misconceptions” surrounding tardive dyskinesia, aiming to “debunk” misinformation that interferes with “quick and effective” clinical intervention.

Day 2:

• Neurology Learning Network Migraine Section Editor Stephanie J. Nahas, MD, MSEd, FAHS, FAAN, associate professor of neurology, Jefferson Headache Center, Thomas Jefferson University, and Shirley Kessel, BS, executive director, Miles for Migraine, explored the “very promising” use of calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) combined with CGRP receptor antagonists (gepants) for the prevention and treatment of migraine.

Day 3:

• Paul B. Rosenberg, MD, professor of psychiatry and behavioral sciences, Johns Hopkins University School of Medicine, reviewed the behavioral and psychological symptoms of dementia (BPSD) that manifest in Alzheimer disease. Dr Rosenberg explained the medications and behavioral interventions that may “provide hope” to patients experiencing the challenges of BPSD as well as ameliorate the caregiver burden.

Day 4:

• Elaine Wirrell, MD, professor and chair, child neurology, Mayo Clinic, Rochester, Minnesota, provided an overview of 3 difficult-to-treat pediatric epilepsies, including Dravet Syndrome, Lennox-Gastaut Syndrome, and Tuberous Sclerosis Complex. Dr Wirrell also highlighted medicinal and nutritional interventions for the conditions, as well as recently approved therapies like pharmaceutical grade CBD, fenfluramine, stiripentol, and everolimus.

Thanks to the unique nature of the virtual format, conference attendees will be able to access session recordings for 30 or 90 days post-conference. Weren’t able to attend Neurology Week 2022 live? You can still register for access here.

For updates about Neurology Week 2023, and for the latest in neuro news from Neurology Learning Network, check out neurologyweek.com for details and to join our mailing list.